Search Results 311-320 of 18008 for Alopecia

1. Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic - Mayo Clinic

   with ongoing alopecia of any grade will be eligible; Patient must have a life expectancy of >= 3 months, as estimated by the treating oncologist; Patient must ...

2. Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 - Mayo Clinic

   alopecia. 15. Receiving herbal supplements or medications known to be strong or moderate inhibitors or inducers of the cytochrome P450 (CYP)2C19 and CYP3A4 ...

3. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

4. A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma - Mayo Clinic

   or greater at the time of starting study treatment except for alopecia. - History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen

5. Skin biopsy - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Diffuse capillary malformation with overgrowth, Vulvar skin disorder, Blue rubber bleb nevus syndrome, Vascular anomaly, Vascular ...

6. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

   Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...

7. A Study to Evaluate Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer - Mayo Clinic

   Exceptions: Residual alopecia and Grade 2 peripheral neuropathy are allowed. Concurrent use of strong and moderate inducers and/or strong inhibitors of ...

8. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - Mayo Clinic

   * Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.

9. Publications - Olayemi Sokumbi, M.D. - Mayo Clinic

   Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid. J Drugs Dermatol. 2022 Aug 1; 21 (8):894-895. View PubMed; Smith SDB, Okoye GA ...

10. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    ... alopecia), or deemed irreversible from the effects of prior cancer therapy; Major surgery, serious infection, or infection requiring systemic antibiotic ...